Testing

This page lists updates posted to Mayo Clinic Labs during the month of September.

By Michael Hutchison • October 2, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

By Barbara J. Toman • September 24, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

By Barbara J. Toman • September 17, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

By Barbara J. Toman • September 10, 2024

This page lists updates posted to Mayo Clinic Labs during the month of August.

By Michael Hutchison • September 5, 2024

Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.

By Barbara J. Toman • August 6, 2024

This page includes updates posted to Mayo Clinic Labs during the month of July.

By Michael Hutchison • August 2, 2024

This page includes updates posted to Mayo Clinic Labs during the month of June.

By Michael Hutchison • July 2, 2024

Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.

By Barbara J. Toman • June 11, 2024

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.

By Barbara J. Toman • June 4, 2024

This page includes updates posted to Mayo Clinic Labs during the month of May.

By Michael Hutchison • June 3, 2024

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.

By Barbara J. Toman • May 14, 2024

This page includes updates posted to Mayo Clinic Labs during the month of April.

By Michael Hutchison • May 2, 2024